

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/140250 A1

(43) International Publication Date
30 June 2022 (30.06.2022)

(51) International Patent Classification:

A61K 31/4164 (2006.01) C07D 487/04 (2006.01)
A61K 31/519 (2006.01) A61P 35/00 (2006.01)
C07D 233/54 (2006.01)

(21) International Application Number:

PCT/US2021/064333

(22) International Filing Date:

20 December 2021 (20.12.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

63/128,635 21 December 2020 (21.12.2020) US

(71) Applicant: BIOCRYST PHARMACEUTICALS, INC.

[US/US]; 4505 Emperor Blvd., Suite 200, Durham, NC
27703 (US).

(72) Inventors: BABU, Yarlagaadda S.; 4836 Southlake Park-

way, Birmingham, AL 35244 (US). SHERIDAN, William
P.; 4505 Emperor Blvd., Suite 200, Durham, NC 27703
(US).

(74) Agent: GORDON, Dana M. et al.; Foley Hoag LLP, 155

Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: DOSING REGIMENS FOR ORAL ALK2 KINASE INHIBITORS

(57) Abstract: Disclosed are dosage forms of compounds and pharmaceutically acceptable salts thereof, which are inhibitors of ALK2 kinase, including mutant forms of ALK2. Also disclosed are methods of using the oral dosage forms in the treatment or prevention of a disease or condition whose treatment would benefit from ALK2 kinase inhibition (e.g., Fibrodysplasia Ossificans Progressiva and cancer).



WO 2022/140250 A1